There are currently 1305 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Healthcare of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT06460298
Recruiting
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia +1 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches
NCT05847621
Recruiting
This is a 3-arm randomized controlled trial. Participants will be randomized via a maximally tolerated imbalance randomization procedure using NCI's Clinical Trial Randomization Tool with 1:1:1 allocation to each group: in-person peer recovery coaching (PRC) with linkage to recovery resources, telemedicine-based peer recovery coaching with linkage to recovery resources, or usual care. In the PRC arms, PRCs will meet patients at bedside (in person) or via a tablet-based video call (telemedicine)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Grady Memorial Hospital, Atlanta, Georgia
Conditions: Substance Use Disorders
Register for Updates
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
NCT04518228
Recruiting
The purpose of this study is to evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
Gender:
FEMALE
Ages:
All
Trial Updated:
08/20/2024
Locations: Emory University School of Medicine NICHD CRS, Atlanta, Georgia
Conditions: HIV Infections, Tuberculosis
Register for Updates
CureDuchenne Link®: A Resource for Research
NCT04972604
Recruiting
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up their child(ren).
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
08/19/2024
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Register for Updates
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
NCT04380740
Recruiting
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/19/2024
Locations: Emory University/Winship Cancer Center, Atlanta, Georgia
Conditions: Graft Vs Host Disease
Register for Updates
Childhood Cancer Survivor Study
NCT01120353
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/19/2024
Locations: Emory University/Children's Health Care of Atlanta, Atlanta, Georgia
Conditions: Cancer
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Grady Health System, Atlanta, Georgia +3 locations
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Bladder Cancer
Register for Updates
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Register for Updates
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
NCT06557902
Recruiting
Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
08/14/2024
Locations: Clinical Site 1, Atlanta, Georgia
Conditions: Autism Spectrum Disorder
Register for Updates
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
NCT06492070
Recruiting
The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cr... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Register for Updates
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
NCT05387915
Recruiting
This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer. HPV positive oropharyngeal cancer has a better prognosis than oropharyngeal cancer not caused by HPV. A standard of care treatment for HPV positive oropharyngeal cancer is transoral robotic surgery followed by radiation therapy. However, this treatment is associated with many long-term side effects including dif... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Emory University Midtown Hospital, Atlanta, Georgia +1 locations
Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma
Register for Updates